Trial Profile
Evaluation of the Effect of Telmisartan on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Aug 2012
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary) ; Telmisartan/hydrochlorothiazide (Primary)
- Indications Cardiovascular disorders; Essential hypertension
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 08 Apr 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
- 08 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Dec 2010 Planned End Date changed from 1 Nov 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.